Stockrabit · Analysts
Questions across 71 calls

Damayanti Kerai

HSBC

Apollo Hospitals Enterprise Limited

Apollo Hospitals Enterprise Limited CC-Sep24.pdf · 2024-11-07
My question is again on GMV trajectory for 24/7. So, you mentioned reverting back to sustainable growth there, but very broadly, I think earlier we said some Rs. 4,000 crore of GMV for this fiscal. So, looking at H1 performance, it definitely looks very back ended in the second half. So, do you think you can still achieve that number? And also, can you update us on some of the new services which were intended for 24/7, especially the IP/OP part and the insurance, how things are progressing there?
And my second question is clarity on this target of 25,000 crore in next three years for the combined pharmacy platform with margins of say 7% to 8%. So, when I look at the skewed first half number , we already are at 6.5% of numbers , right, if we exclude the digital expense. So, with topline improving almost 1.5x from current level, do you expect like margins could be better or that 7% to 8% is the number which you are intending to achieve?
Apollo Hospitals Enterprise Limited CC-Dec23.pdf · 2024-02-09
My first question is on margin trajectory for hospital segment. So ma'am, obviously, you mentioned you are investing in clinical talent for new facility, etcetera. And we have seen margins falling off from, say, mid -20s to around 23 %, 23.5% or so. So , can you elaborate like how should we look at this margin profile over next few quarters? Because you have a couple of hospitals commen cing operation in FY 25. So that's my question on hospital margins.
So, this 200-basis point margin improvement is for existing set of beds or whatever like new beds will come cumulatively, you're talking about the sort of...

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited CC-Sep24.pdf · 2024-11-05
Hi, thank you for the opportunity. My question is on R&D. So, you mentioned you are focusing on high -quality R&D. So , can you just talk about the segments or products which you are working on? And do you think you can launch some material products in, say, next 1 to 2 years in the US market, specifically, which can help you to cover up some sales lost on the Revlimid part. So that's my first question.
Sure. My related question is you mentioned peptides, GLP-1 is one of your focus segments. On the R&D part, I understand you are covering the entire product basket, which will open up in market in coming years. But on the manufacturing part, do you have in -house manufacturing capability, or you intend to get it done through some manufacturing partners?
Dr. Reddy's Laboratories Limited CC-Jun24.pdf · 2024-07-27
Hi. Thank you for the opportunity. Continuing on India, so, I just want to understand now, Sanofi vaccines contributed meaningfully in your India numbers. Is this the current base which we should assume? Like you will be growing from the base of 1Q in coming quarters or how should we look at India growth in near term as well as in medium term?
Okay. And this base business, you said, it grew in single digits during the quarter excluding the acquisition.

Cipla Limited

Cipla Limited CC-Sep24.pdf · 2024-10-29
My first question is on Ambraxane opportunity. So obviously I think we are waiting for Goa clearance for this particular product. But can you comment in case we don't heard back favorably from the USFDA regarding classification etc. How far this product can be pushed in terms of launch in the market? If I remember correctly, earlier you said this launch could possibly come in second half of FY25. So what is your recent thought on this product?
Okay, in case Goa takes slightly longer, then you proceed with the CMO route, then how long I guess we have to wait?

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited CC-Jun24.pdf · 2024-08-16
My first question is like you have seen a good pickup in India. So that, I guess, very comforting. But looking at U.S., I guess, still remains a bit soft. So what are your expectations on U.S. sales recovery? And how do you see -- like do you have any visibility on FDA regulation for Monroe plant?
Okay. So better U.S. we should be assuming starting second half. So even if, say, Monroe takes some time, you mentioned you have a couple of respiratory products. If those come, those should be -- may contribute meaningfully and then see better U.S. sales?
Glenmark Pharmaceuticals Limited CC-Dec23.pdf · 2024-02-16
My first question is on India business restructuring. So Glenn, can you elaborate a bit more like what has prompted you to take this restructuring? And what are the key points which you want to achieve through this process? And after this process, do you think India business is now in good shape to cater to your requirements? So that's my first question.
Just wanted to understand, was your distribution model very different from what your peers have in India market?
Glenmark Pharmaceuticals Limited CC-Sep23.pdf · 2023-11-15
I just need some more clarity on margins. So obviously , you mentioned '24 will be a transition year and then for FY25 you mentioned 200 basis points better margins on the core business part. But for the quarter, say if I look at the numbers , 14.4%, I'm excluding the FOREX part, so that is anyway I think looking much lower than what we had seen previously. So, can you specify whether the slower performance in India and US contributed majorly towards it and maybe in 3rd Quarter and fourth quarter as India and US comes back, we'll see better margins?
So, you maintain that 19% margin trajectory for your business?

Rainbow Childrens Medicare Limited

Rainbow Childrens Medicare Limited CC-Jun24.pdf · 2024-08-14
Hi, good morning and thank you for the opportunity. My first question is on costs related to new units. So just want to understand whether the first quarter numbers reflect most of the costs which you have incurred or you expect to incur on an ongoing basis for the new units or do you have a plan to add on more doctors, more people, etc there? So som e color on that will be helpful?
Understood. So in terms of margin, we understand your September and December quarter very healthy, but on an annual basis, how should we think about improvement or change from the FY24 level?

IPCA Laboratories Limited

IPCA Laboratories Limited CC-Jun24.pdf · 2024-08-14
Sir, you mentioned the shortfall on the export side, which you have seen in 1 quarter that might not be bridged. So, how do you see the overall expo rt growth for the market? And in terms of profitability at the consolidated level, what are your expectations for FY ‘25?
Okay. That’s helpful, sir. And my second question i s if you can update us on your advancement in the U.S. market in terms of how you’ re advancing in supplies or in filing for the market? Like I understand, it’s slightly longer term to scale up, but nonetheless, if you can talk about the progress which you have seen so far?
IPCA Laboratories Limited CC-Sep23.pdf · 2023-11-10
Thank you for the opportunity. Sir my question is on your margin trajectory so lot of cost initiative happening at Unichem portfolio as well a s your own so like Q2 number includes two months of Unichem business? Looking ahead how d o you see cost like dynamics changing and how do you see margins say in near ter m and then in slightly longer term in terms of like trajectory movement?
Okay so at least 100 basis points improvement per year that is good to hear Sir and then I wanted to check update on the Devas plant? You said it is yet to be offered to agency so what is the timeline like when you are planning to invite some major regulators?

Global Health Limited

Krishna Institute of Medical Sciences Limited

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited CC-Mar24.pdf · 2024-05-24
My first question is on India business. So, you ended the year at 14% growth. So, how should we look at growth trajectory in FY25 from this high base and if you can also talk a bit about the key growth drivers in terms of price, volume or contribution?
So, this price contribution obviously is on higher side compared to I guess in the prior year. So, should we assume some moderation there or do you think this high single digit kind of price contribution can be sustained?

Alkem Laboratories Limited

Alkem Laboratories Limited CC-Dec23.pdf · 2024-02-09
My question is to Dr. Vikas. So you mentioned like you have been focusing on some key growth areas, you are working on co st optimization initiatives, et c. And despite that, at least in near term, I guess, you are keeping your margin expectation of around 17%. So I just wanted to understand, say, in medium term, what kind of margin aspirations you are having? And also, I guess, on India part, it remains majority of -- sorry, acute therapy portfolio. So say, next 3 to 5 years, what kind of mix you are looking between acute and chronic therapies in India?
Okay. So say, next 3 to 5 years with a substantial pickup in chronic and then R OW business doing very well, etc. Should we assume like 20% kind of margin is not unachievable for Alkem?

Max Healthcare Institute Limited

Divi's Laboratories Limited

Divi's Laboratories Limited CC-Sep23.pdf · 2023-11-06
Sir, my first question is on contrast media opportunity. So you obviously talked about ramp-up, which is happening in your business. So can you elaborate a bit, like what is the progress in the Iodine-based supply so far? And what is the progress on the G adolinium-based product development part? That's my first question.
So for Gadolinium-based most likely towards end of this fiscal, you expect to start supplies and then pick up will maybe more in next fiscal year?